GSK's tuberculosis vaccine shows promising results
The new vaccine, known as M72/AS01E, was tested at 11 sites in Kenya, South Africa and Zambia in adults whose blood tests showed they had latent TB. The study revealed that the vaccine could cut the number of people developing TB by half.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: African Health | Biotechnology | Kenya Health | Pharmaceuticals | South Africa Health | Study | Tuberculosis | Tuberculosis (BCG) Vaccine | Vaccines | Zambia Health